These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27599816)

  • 1. [Rivastigmine and Parkinson's disease without dementia : Impact on gait stability and frequency of falling].
    Amadori K
    Z Gerontol Geriatr; 2016 Oct; 49(7):662-663. PubMed ID: 27599816
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Henderson EJ; Lord SR; Brodie MA; Gaunt DM; Lawrence AD; Close JC; Whone AL; Ben-Shlomo Y
    Lancet Neurol; 2016 Mar; 15(3):249-58. PubMed ID: 26795874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen.
    Henderson EJ; Lord SR; Close JC; Lawrence AD; Whone A; Ben-Shlomo Y
    BMC Neurol; 2013 Dec; 13():188. PubMed ID: 24299497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study.
    Mamikonyan E; Xie SX; Melvin E; Weintraub D
    Mov Disord; 2015 Jun; 30(7):912-8. PubMed ID: 25914281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson's disease.
    Koshy Cherian A; Kucinski A; Wu R; de Jong IEM; Sarter M
    Psychopharmacology (Berl); 2019 Jun; 236(6):1701-1715. PubMed ID: 30607479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson's Disease Patients.
    Li Z; Yu Z; Zhang J; Wang J; Sun C; Wang P; Zhang J
    Eur Neurol; 2015; 74(1-2):86-91. PubMed ID: 26288230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholinesterase inhibitor to prevent falls in Parkinson's disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson's disease.
    Neumann S; Taylor J; Bamford A; Metcalfe C; Gaunt DM; Whone A; Steeds D; Emmett SR; Hollingworth W; Ben-Shlomo Y; Henderson EJ
    BMC Neurol; 2021 Oct; 21(1):422. PubMed ID: 34715821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetylcholinesterase inhibitors and gait: a steadying hand?
    Moreau C; Devos D; Defebvre L
    Lancet Neurol; 2016 Mar; 15(3):232-3. PubMed ID: 26795875
    [No Abstract]   [Full Text] [Related]  

  • 9. ExPPNing how acetylcholine improves gait in Parkinson's disease: An Editorial Highlight for 'Deletion of the Vesicular Acetylcholine Transporter from Pedunculopontine/laterodorsal tegmental neurons modifies gait'.
    Falkenburger B
    J Neurochem; 2017 Mar; 140(5):688-691. PubMed ID: 28058727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep brain stimulation effects on gait variability in Parkinson's disease.
    Hausdorff JM; Gruendlinger L; Scollins L; O'Herron S; Tarsy D
    Mov Disord; 2009 Aug; 24(11):1688-92. PubMed ID: 19554569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
    Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R;
    Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
    Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R
    Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 24 h Levodopa-carbidopa intestinal gel may reduce falls and "unresponsive" freezing of gait in Parkinson's disease.
    Chang FC; Tsui DS; Mahant N; Wolfe N; Kim SD; Ha AD; Drury M; Griffith JM; Fung VS
    Parkinsonism Relat Disord; 2015 Mar; 21(3):317-20. PubMed ID: 25578290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivastigmine for dementia associated with Parkinson's disease.
    Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
    N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacological hypotheses and therapeutic strategies for gait disorders in Parkinson's disease].
    Devos D; Bordet R; Defebvre L
    Rev Neurol (Paris); 2010 Feb; 166(2):168-77. PubMed ID: 19811797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin type B for gait freezing in Parkinson's disease.
    Fernandez HH; Lannon MC; Trieschmann ME; Friedman JH
    Med Sci Monit; 2004 Jul; 10(7):CR282-4. PubMed ID: 15232500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
    Darreh-Shori T; Jelic V
    Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Trial of Oral and Transdermal Rivastigmine for Postural Instability in Parkinson Disease Dementia.
    McDonald J; Pourcher E; Nadeau A; Corbeil P
    Clin Neuropharmacol; 2018; 41(3):87-93. PubMed ID: 29537978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living.
    Olin JT; Aarsland D; Meng X
    Dement Geriatr Cogn Disord; 2010; 29(6):510-5. PubMed ID: 20523050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of falling in Parkinson's disease at the Hoehn-Yahr stage III.
    Kataoka H; Tanaka N; Eng M; Saeki K; Kiriyama T; Eura N; Ikeda M; Izumi T; Kitauti T; Furiya Y; Sugie K; Ikada Y; Ueno S
    Eur Neurol; 2011; 66(5):298-304. PubMed ID: 22057308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.